When patients with schizophrenia initiate second-generation antipsychotic therapy, clinicians commonly monitor weight as an early warning sign of metabolic harm. However, findings from a recent electronic health record study of adults suggest that blood glucose levels may rise soon after treatment begins, underscoring the need for earlier glucose monitoring in this population.
Also Read
- Republican Congressman Backs Medicaid Work Rules While His District May Qualify for Exemption
- Ohio’s Medicaid Home‑Care Enrollment Freeze Nears Nov. 14 End Amid Growing Care‑Gap Concerns for Disabled Residents
- Midstream Health Raises $20M to Deliver Greater Financial Stability to Health Systems
- Setara Biosciences Launches With $90 Million Series A and Clinical-Stage Rare Disease Pipeline
